CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Episodes 361-375 of 739
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
CME/CEFAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Patient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival
CME/CE Broadcast ReplayPatient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
MinuteCE®Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
MinuteCE®The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
MinuteCE®Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
- advertisement
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
MinuteCE®Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®From Guidelines to Practice: First-Line Treatment Choices in mCRC
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
MinuteCE®Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
MinuteCE®ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
- advertisement
Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
MinuteCE®Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
MinuteCE®Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
MinuteCE®The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
